---
title: "Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291607457.md"
description: "Lynx1 Capital Management disclosed a 21.0% stake in Passage BIO, filing a Schedule 13D on July 2, 2026, after crossing the 20% threshold. This shift from passive to active ownership coincides with Passage BIO's planned merger with Remix Therapeutics. Lynx1 joined concurrent financing for the merger and intends to engage with management regarding strategy and governance."
datetime: "2026-07-03T01:26:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291607457.md)
  - [en](https://longbridge.com/en/news/291607457.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291607457.md)
generator: "portal-rs"
---

# Lynx1 Capital Management Discloses Investment at Passage BIO with 21.0% Stake

Lynx1 Capital Management LP disclosed a 21.0% stake in Passage BIO, Inc. common stock. The firm filed a Schedule 13D on Jul. 02, 2026 after moving from a passive 13G because its ownership crossed 20%. The shift signals a more active posture as Passage BIO moves to merge with Remix Therapeutics.

**Investor Intent**

Lynx1 agreed to join a concurrent financing tied to Passage BIO’s merger with Remix Therapeutics, buying Remix common stock and convertible notes and securing registration rights for resale. The fund expects to receive additional Passage BIO shares at the merger’s effective time and will also receive one contingent value right per Passage BIO share held before closing.

Lynx1 may discuss business strategy, capital structure, governance, and the merger with company leaders and other investors. "We expect to receive additional Passage BIO shares when the Remix merger closes," and "We may talk with management and other shareholders about strategy and the merger."

**Investor's Background**

Lynx1 Capital Management LP is a Delaware limited partnership that serves as the investment manager to Lynx1 Master Fund LP. Chief Investment Officer Weston Nichols oversees the firm’s portfolio decisions. The firm focuses on public equities and event-driven situations, often taking concentrated positions and engaging on strategic outcomes.

Original SEC Filing: Passage BIO, Inc. \[ PASG \] - SCHEDULE 13D - Jul. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PASG.US](https://longbridge.com/en/quote/PASG.US.md)

## Related News & Research

- [Passage Bio announces $70 million private placement at $1.39 per share, including pre-funded warrants](https://longbridge.com/en/news/297895358.md)
- [Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE](https://longbridge.com/en/news/297896887.md)
- [YD Bio Files First-Half 2026 Results, Reports Improved Equity Position](https://longbridge.com/en/news/297639743.md)
- [Trade Desk BDRs in Brazil undergo 1-for-100 reverse stock split on Sept. 21 after ratio reset](https://longbridge.com/en/news/297689924.md)
- [Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i](https://longbridge.com/en/news/297634988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**